INSULIN RESISTANCE IN MOOD DISORDERS

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 世纪上半叶的文献表明，严重精神疾病与糖尿病或葡萄糖耐受不良之间存在关联。 严重情绪障碍患者风险增加的机制尚不清楚，但糖皮质激素升高，交感神经系统激活，进食行为失调，自我护理不良，共病疾病如吸烟或饮酒，以及社会人口风险因素如社会经济地位低，获得医疗保健的机会少，社会支持差，被认为会增加体重增加的风险，胰岛素抵抗和2型糖尿病。 在患有情绪障碍和糖尿病或胰岛素抵抗的患者中观察到更大的认知缺陷。 本研究旨在检查胰岛素抵抗对抑郁症患者基线时神经认知指标的影响，并在胰岛素增敏药物（二甲双胍）治疗90天后再次检查。 我们假设，参与者与高水平的胰岛素抵抗，确定对葡萄糖耐量试验的反应，将显示更大的认知缺陷。 此外，我们假设胰岛素抵抗的参与者在接受胰岛素增敏药物治疗后会表现出认知改善。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Literature from the first part of the 20th century suggested an association between severe mental illness and diabetes or glucose intolerance. The mechanism by which patients with a major mood disorder have increased risk is not known, but elevated glucocorticoids, activation of the sympathetic nervous system, dysregulated feeding behavior, poor self care, comorbid disorders such as tobacco or alcohol use, and sociodemographic risk factors such as low socioeconomic status, poor access to health care, and poor social support, have been thought to increase the risk of weight gain, insulin resistance, and type 2 diabetes. Greater cognitive deficits are observed in patients with both mood disorders and with diabetes or insulin resistance. The present study seeks to examine the effects of insulin resistance on neurocognitive measures in depressed patients at baseline and again after 90 days of an insulin-sensitizing medication (Metformin). We hypothesize that participants with high levels of insulin resistance, as determined by response to glucose tolerance testing, will show greater cognitive deficits. Further, we hypothesize that participants with insulin resistance will demonstrate cognitive improvement after treatment with an insulin-sensitizing medication.